Faculty introduction and disclosures

NPC identification and burden ●       Epidemiology and global distribution of NPC ●       Risk factors for NPC, recurrence, and distant metastases ●       Burden of disease

Integrating novel and emerging treatments for recurrent or metastatic NPC ●       First-line therapy ○       Combination chemotherapy: gemcitabine/cisplatin vs other options ○       Consideration of the addition of immunotherapy ●       Later-line therapy decision-making  ○       Immunotherapy vs. chemotherapy ○       Role of biomarkers ○       Choice of immunotherapy ●       Investigational agents ○       Novel agents ○       Novel combinations ○       Encouraging consideration of clinical trial enrollment ●       Importance of the MDT  ○       Strategies for multidisciplinary care ○       Selecting and sequencing localized and systemic therapy ○       Recognition, management, and mitigation of treatment-related adverse events, including in patients receiving immunotherapy ○       Related patient education and patient-reported outcomes ●       Putting it all together: patient case(s)

Summary, conclusions, and best practice recap

By the end of the session the participant will be able to:

• Review risk factors for the development and progression of NPC, including the identification of patients at high risk for distant metastases.
• Compare systemic treatment regimens available for the management of recurrent or metastatic NPC.
• Evaluate the evidence supporting the safety and efficacy of various treatment approaches for recurrent or metastatic NPC.
• Individualize treatment for a patient with metastatic NPC using guideline recommendations and multidisciplinary strategies.

ACCME Activity #203279196

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosures of Faculty: Michael Dennis, MD, Medical Oncologist, Division of Head and Neck Oncology, Harvard Medical School, has received financial compensation from Coherus BioSciences and Corbus Pharmaceuticals as a consultant; in addition to speaker’s bureau work for Dr. Reddy’s Laboratories.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.  

Faculty WILL NOT discuss off-label uses of a commercial product. 

All relevant financial relationships have been mitigated. 

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Coherus BioSciences. 

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version